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Family history of haematopoietic malignancies appears to be a risk factor for non-Hodgkin’s lymphoma (NHL), but whether risk varies
by family member’s gender is unclear. Among 121216 women participating in the prospective California Teachers Study, NHL risk
varied by type of haematopoietic malignancy and gender of the relative.
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Evidence from epidemiologic studies shows that the risk of non-
Hodgkin’s lymphoma (NHL) is increased by approximately
twofold for individuals with a first-degree family history (parent,
sibling or child) of haematopoietic malignancy (Pottern et al, 1991;
Zhu et al, 1998; Chiu et al, 2004; Altieri et al, 2005; Chang et al,
2005; Goldin et al, 2005; Wang et al, 2007). However, the
underlying mechanisms are poorly understood.
A recent analysis from the International Lymphoma Epidemio-
logy (InterLymph) Consortium of NHL case–control studies found
an increased risk of NHL for individuals who reported having
a first-degree relative with a haematopoietic malignancy
(NHL, Hodgkin’s lymphoma, leukaemia or multiple myeloma)
(Wang et al, 2007). They also found that NHL risk differed by the
gender and familial relationship of the affected relative. These
findings were based on case–control studies using retrospectively
self-reported data on family history, and were therefore potentially
subject to survival bias and differential recall bias (Chang et al,
2006). To understand the underlying disease mechanisms in NHL
better, we used data from the prospective California Teachers
Study to investigate NHL risks associated with first-degree family
history.
MATERIALS AND METHODS
A detailed description of the California Teachers Study has been
published elsewhere (Bernstein et al, 2002). In this analysis, we
included 121216 women who were California residents, were
under the age of 85 years at baseline and had no prior history of a
haematopoietic malignancy. Use of human subjects in this study
was approved by each participating institution.
Incident diagnoses of B-cell NHL (International Classification of
Diseases for Oncology third edition morphology codes: 9590, 9591,
9670–9675, 9680–9699, 9727, 9823, 9832, 9835 and 9836) were
identified through annual linkages with the population-based
California Cancer Registry. Person-time was accrued from the date
a participant completed her baseline questionnaire until the first
occurrence of either a diagnosis of a B-cell NHL or a censoring
event: a move outside of California; a first diagnosis of another
haematopoietic malignancy not included in our case definition;
death; or 31 December 2005.
The self-administered, baseline questionnaire collected detailed
information on personal and family history of cancer. Having
‘no family history’ of a haematopoietic malignancy was defined as
reporting no first-degree relative with NHL, Hodgkin’s lymphoma
or leukaemia.
We used Cox proportional hazards regression models, stratified by
age in years at baseline, to estimate hazard rate ratios (RR) and 95%
confidence intervals (CIs) for B-cell NHL, using age in days from
baseline until the end of follow-up for the time under observation. We
assessed potential confounders including race; history of a full-term
pregnancy; baseline residential socioeconomic status, smoking status,
height and body mass index (BMI); and alcohol consumption 1 year
before baseline. We did not include any of these variables in our final
statistical models as none changed the risk estimates by as much as
5%. All statistical analyses were performed using SAS version 9.1
(SAS Institute Inc.).
RESULTS
During an average of 9.3 years of follow-up, 478 California
Teachers Study participants were diagnosed with B-cell NHL.
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according to family history of lymphoma or leukaemia. Overall,
5.1% of the participants had a first-degree family history of
lymphoma or leukaemia. Non-Hispanic white women, older
women and women with higher BMI were more likely to have an
affected first-degree relative. Family history did not differ
according to socioeconomic status, smoking status or alcohol
consumption.
A history of haematopoietic malignancy in any first-degree
relative was associated with a significant increased risk of
B-cell NHL (RR¼1.52, 95% CI¼1.11–2.07) (Table 2). Risk
of B-cell NHL was significantly elevated for women who reported
having a first-degree relative with NHL or Hodgkin’s lymphoma
(RR¼1.74, 95% CI¼1.16–2.60), but was not associated
with having a first-degree relative diagnosed with a leukaemia
(RR¼1.35, 95% CI¼0.87–2.09), when compared with women
with no family history of any haematopoietic malignancy.
Meanwhile, risks varied significantly by the gender of the
affected family member. Women reporting a female relative with
lymphoma had a 2.5-fold greater risk of B-cell NHL than those
with no family history of any haematopoietic malignancy
(RR¼2.48, 95% CI¼1.53–4.04), but those reporting a male
relative with lymphoma were not at increased risk (RR¼1.14,
95% CI¼0.59–2.21). In contrast, an increased risk of B-cell NHL
was found among women who had a first-degree male relative
with leukaemia (RR¼1.76, 95% CI¼1.05–2.94), but not a female-
affected relative (RR¼0.95, 95% CI¼0.45–2.01), compared
with women with no family history of any haematopoietic
malignancy.
The association with a parental-based family history of
lymphoma or leukaemia was comparable with that of a sibling-
based family history (results not shown). Similar to the associa-
tions based on gender, women having a lymphoma-affected
mother had the elevated NHL risk (RR¼2.92, 95% CI¼1.60–
5.31), as did those having a leukaemia-affected father (RR¼2.17,
95% CI¼0.1.19–3.95) (results not shown).
DISCUSSION
Our cohort study results confirm the evidence from population-
based case–control studies and registry-based linkage studies of
an increased NHL risk among individuals with a family history of
haematopoietic malignancy (Pottern et al, 1991; Zhu et al, 1998;
Chiu et al, 2004; Altieri et al, 2005; Chang et al, 2005; Goldin et al,
2005). The magnitudes of our RR estimates are closer to those
from registry-based studies, in which family history data are
verified, than to those from case–control studies, in which family
history is generally self-reported and, therefore, subject to
misclassification and recall bias.
We found that the association with a first-degree family history
of haematopoietic malignancy varied by gender, being stronger for
female relatives with a history of lymphoma and for male relatives
with a history of leukaemia, as reported earlier from population-
based registries (Czene et al, 2007). Among women in their study,
those who had an affected female relative with haematopoietic
malignancy had a higher RR of NHL than those with an affected
male relative. Our study results differ from the InterLymph
consortium results for women, a pooled analysis of 17 NHL case–
control studies (11 population-, 6 hospital-based) (Wang et al,
2007). In InterLymph, RRs were higher when the family history
involved lymphoma in a male, or leukaemia in a female, relative;
Table 1 Selected baseline characteristics of 121216 eligible women in
the California Teachers Study in relation to family history of haematopoietic
malignancy at baseline
Family history of lymphoma or
leukaemia
N No Yes Not known
Total 121216 113225 6165 1826
Age at cohort entry (years)
o35 12741 10.7 4.0 18.2
35–44 21448 17.9 13.5 19.2
45–54 36468 30.1 29.3 30.8
55–64 23475 19.2 23.3 15.3
65–74 17797 14.5 19.1 11.5
75–84 9287 7.5 10.8 5.1
Age-adjusted percentages
Race
Non-Hispanic white 104814 86.6 89.0 81.4
All other races/ethnicities 15405 12.7 10.3 13.9
Unknown race/ethnicity 997 0.7 0.7 4.7
Socioeconomic status quartile rank
1st (low) 5287 4.1 4.0 4.5
2nd 20799 16.3 16.0 17.6
3rd 39228 32.0 31.5 33.7
4th (high) 54356 46.4 47.3 43.0
Unknown 1546 1.3 1.2 1.2
Smoking status
Never 79627 64.8 63.2 62.8
Former 34684 29.4 31.2 29.2
Current 6181 5.2 5.2 7.6
Unknown 724 0.6 0.4 0.5
Alcohol consumption (g
 1 day)
None 38619 31.3 31.8 30.4
o15 56970 48.3 46.3 47.4
X15 19301 16.1 17.3 17.4
Unknown 6326 4.3 4.6 4.8
Body mass index (kgm
 2)
o20 12651 48.4 47.0 44.1
20–24.9 58204 10.1 9.3 9.8
25–29.9 29100 24.1 25.0 24.2
X30 16414 14.1 15.4 17.6
Unknown 4847 3.3 3.3 4.3
Number of siblings
0 11878 10.1 8.3 0.2
1 35560 30.4 28.0 0.1
2 30147 25.6 24.7 —
3 18147 15.3 16.1 —
4+ 21804 17.3 21.7 0.1
Adopted/unknown 3680 1.4 1.3 99.6
Table 2 Relative risk estimates and 95% confidence intervals for the
association between family history of haematopoietic malignancy and B-cell
NHL risk among women in the California Teachers Study
Family history
Total person-
years
Number of
cases RR (95% CI)
None 1053996 432 1.00
Lymphoma 29620 25 1.74 (1.16–2.60)
Male relative 16572 9 1.14 (0.59–2.21)
Female relative 13601 17 2.48 (1.53–4.04)
Leukaemia 29211 21 1.35 (0.87–2.09)
Male relative 16653 15 1.76 (1.05–2.94)
Female relative 12960 7 0.95 (0.45–2.01)
Any lymphoma or
leukaemia
57153 44 1.52 (1.11–2.07)
Male relative 32635 24 1.49 (0.99–2.25)
Female relative 26037 22 1.58 (1.03–2.43)
Abbreviations: CI¼confidence interval; NHL¼non-Hodgkin’s lymphoma;
RR¼relative risk.
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60% (cases) and some control rates below 50%. Moreover, RRs
varied widely across individual studies in the InterLymph report.
Therefore, selection bias in case–control studies, especially from a
survival bias, is of particular concern if the pattern of NHL
heritability is also associated with aggressiveness of NHL subtype
or with NHL survival more generally. Although the InterLymph
report provided risk estimates for major B-cell NHL subtypes
(Wang et al, 2007), we were unable to evaluate such risks due to
the small number of cases with a family history.
A limitation of our study is that our family history reports were
self-reported. Concerns regarding the accuracy of self-reported
family history of lymphoma were raised previously in a Swedish
study (Chang et al, 2006), in which such a history was validated
against population-based registries. In that study, the specificity of
reporting haematopoietic malignancy was extremely high for both
lymphoma cases and controls (98 and 99%, respectively), but the
sensitivity was 60% for lymphoma cases and only 38% for controls.
This resulted in a higher estimated RR of NHL associated with
family history of haematopoietic malignancy when using self-
reported data rather than registry-based data. Our self-reported
family history probably reflects some degree of misclassification,
but this is unlikely to be differential, and would tend to bias our
RR estimate towards the null as our family history reports were
obtained at study entry. Further, it is unlikely that the accuracy of
self-reported data differed by gender of the affected relative.
As we asked about family history of lymphoma separately
from that of leukaemia, it is possible that participants with a family
history of CLL reported this as a leukaemia, not as a lymphoma,
though CLL is part of the NHL case definition (Jaffe et al, 2001).
When we excluded women with CLL from our case group,
censoring them on their dates of diagnosis, we obtained essentially
the same results as shown in Table 2 in which risk for NHL was
associated with having a male relative with leukaemia.
A final limitation is that we did not ascertain cancer diagnoses
among participants’ relatives during the follow-up period. Given
that cohort members who developed NHL, compared with those
who did not, would be more likely to have had additional familial
diagnoses of haematopoietic malignancy, our RR estimates may
underestimate the true association with first-degree family history.
In summary, we confirmed a positive association between family
history of haematopoietic malignancy and NHL risk.
ACKNOWLEDGEMENTS
This study was supported by the National Institutes of Health
(CA77398); the National Cancer Institute’s Surveillance, Epide-
miology and End Results Program (N01-PC-35139 awarded to the
University of Southern California; N01-PC-35136 awarded to the
Northern California Cancer Center; and N02-PC-15105 awarded to
the Public Health Institute); the Centers for Disease Control and
Prevention’s National Program of Cancer Registries (agreement
no. U55/CCR921930-02 awarded to the Public Health Institute);
and by the California Breast Cancer Act of 1993, California
Department of Health Services, which supported the collection of
cancer incidence data as part of the statewide cancer-reporting
programme mandated by California Health and Safety Code
Section 103885. The ideas and opinions expressed herein are those
of the authors, and endorsement by the State of California,
Department of Health Services, the National Cancer Institute, and
the Centers for Disease Control and Prevention or their
contractors and subcontractors is not intended nor should be
inferred.
REFERENCES
Altieri A, Bermejo JL, Hemminki K (2005) Familial risk for non-Hodgkin
lymphoma and other lymphoproliferative malignancies by histopatho-
logic subtype: the Swedish Family-Cancer Database. Blood 106:
668–672
Bernstein L, Allen M, Anton-Culver H, Deapen D, Horn-Ross PL, Peel D,
Pinder R, Reynolds P, Sullivan-Halley J, West D, Wright W, Ziogas A,
Ross RK (2002) High breast cancer incidence rates among California
teachers: results from the California Teachers Study (United States).
Cancer Causes Control 13: 625–635
Chang ET, Smedby KE, Hjalgrim H, Glimelius B, Adami HO (2006)
Reliability of self-reported family history of cancer in a large case–
control study of lymphoma. J Natl Cancer Inst 98: 61–68
Chang ET, Smedby KE, Hjalgrim H, Porwit-MacDonald A, Roos G,
Glimelius B, Adami HO (2005) Family history of hemato-
poietic malignancy and risk of lymphoma. J Natl Cancer Inst 97:
1466–1474
Chiu BC, Weisenburger DD, Zahm SH, Cantor KP, Gapstur SM, Holmes F,
Burmeister LF, Blair A (2004) Agricultural pesticide use, familial cancer,
and risk of non-Hodgkin lymphoma. Cancer Epidemiol Biomarkers Prev
13: 525–531
Czene K, Adami HO, Chang ET (2007) Sex- and kindred-specific familial
risk of non-Hodgkin’s lymphoma. Cancer Epidemiol Biomarkers Prev 16:
2496–2499
Goldin LR, Landgren O, McMaster ML, Gridley G, Hemminki K, Li X,
Mellemkjaer L, Olsen JH, Linet MS (2005) Familial aggregation and
heterogeneity of non-Hodgkin lymphoma in population-based samples.
Cancer Epidemiol Biomarkers Prev 14: 2402–2406
Jaffe ES, Harris NL, Stein H, Vardiman J (2001) Pathology and Genetics of
Tumours of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon,
France
Pottern LM, Linet M, Blair A, Dick F, Burmeister LF, Gibson R, Schuman
LM, Fraumeni Jr JF (1991) Familial cancers associated with subtypes of
leukemia and non-Hodgkin’s lymphoma. Leuk Res 15: 305–314
Wang SS, Slager SL, Brennan P, Holly EA, De Sanjose S, Bernstein L,
Boffetta P, Cerhan JR, Maynadie M, Spinelli JJ, Chiu BC, Cocco PL,
Mensah F, Zhang Y, Nieters A, Dal Maso L, Bracci PM, Costantini AS,
Vineis P, Severson RK, Roman E, Cozen W, Weisenburger D, Davis S,
Franceschi S, La Vecchia C, Foretova L, Becker N, Staines A, Vornanen
M, Zheng T, Hartge P (2007) Family history of hematopoietic
malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled
analysis of 10211 cases and 11905 controls from the International
Lymphoma Epidemiology Consortium (InterLymph). Blood 109:
3479–3488
Zhu K, Levine RS, Gu Y, Brann EA, Hall I, Caplan LS, Baum MK (1998)
Non-Hodgkin’s lymphoma and family history of malignant tumors in a
case–control study (United States). Cancer Cause Control 9: 77–82
Family history of haematopoietic malignancies and NHL
YL uet al
526
British Journal of Cancer (2009) 100(3), 524–526 & 2009 Cancer Research UK
E
p
i
d
e
m
i
o
l
o
g
y